Invasive Ductal Carcinoma of the Breast in a Transgender Man: A Case Report

• Published in: Case reports in oncology Vol. 16; no. 1; pp. 811 - 817
• Main Authors: Heng, Yujing J., Zhang, Kevin J., Valero, Monica G., Baker, Gabrielle M., Fein-Zachary, Valerie J., Irwig, Michael S., Wulf, Gerburg M.
• Format: Journal Article
• Language: English
• Published: Basel, Switzerland S. Karger AG 01-01-2023; Karger Publishers
• Subjects: Biopsy; Breast cancer; Cancer therapies; Case Report; Case reports; Chemotherapy; Clinical practice guidelines; Conflicts of interest; Estrogens; Family medical history; gender dysphoria; Histology; Hyperplasia; Lymphatic system; Medical screening; Menopause; Non-binary gender; Oophorectomy; Ovaries; Prevention; Radiation; Testosterone; Transgender persons; transmasculine; Womens health; United States > US; Testosterone; Breast cancer; Transmasculine; Gender dysphoria
• ISSN: 1662-6575; 1662-6575
• DOI: 10.1159/000529859

Abstract
There is limited literature about breast cancer in the transgender population. Very little is known about how gender-affirming hormone therapy affects their breast cancer risk. On the other end, for those diagnosed with breast cancer, there are no clinical guidelines to manage their breast cancer, specifically, how to manage their gender-affirming hormone therapy during breast cancer treatment. Here, we report a 52-year-old transman diagnosed with a grade 2 invasive ductal carcinoma (ER+/PR+/HER2−), and ductal carcinoma in situ (DCIS) of intermediate grade. We discussed his risk factors as well as treatment options.